Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of volitinib in treating patients
with primary central nervous system (CNS) tumors that have come back (recurrent) or does not
respond to treatment (refractory). Volitinib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.